Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 109 UK neurodegenerative disease companies below.
Specialty pharmaceuticals for Parkinson's disease and related neurological conditions
Britannia Pharmaceuticals is a UK-based specialty pharmaceutical company developing and marketing treatments for Parkinson's disease and related conditions including psychosis. The company's product range includes apomorphine-based therapies available in multiple delivery formats, alongside clozapine-based treatment…
Engineered iPSC-derived exosomes for tissue-targeted drug delivery
Excellio Labs is a biotech developing engineered exosome platforms for targeted drug delivery. The technology exploits the inherent tissue-specificity of iPSC-derived extracellular vesicles, which are further surface-modified to create precision drug carriers capable of delivering nucleic acids, proteins, and small…
Small molecule protein degraders targeting oncology and CNS disease
Kesmalea Therapeutics is a biotechnology company developing oral small molecule therapeutics that modulate protein homeostasis through targeted protein degradation and stabilisation. The company's platform is designed to convert the potency of protein degrader approaches into orally bioavailable, CNS-penetrant small…
Small molecule remyelination therapeutics for neurological diseases
Pheno Therapeutics is a Scottish clinical-stage biotechnology company developing small molecule therapeutics that promote remyelination by boosting the function of oligodendrocytes in the central nervous system. Its lead programme PTD802, a selective GPR17 antagonist licensed from UCB, received MHRA clinical trial…
Antisense oligonucleotide therapies for TUBB4A-associated leukodystrophies
SynaptixBio is a biotechnology company developing antisense oligonucleotide therapies for severe inherited leukodystrophies. Its lead programme targets TUBB4A-associated hypomyelinating disorders, including hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). The approach uses synthetic…
AI-driven target identification and drug discovery from omics data
Intelligent OMICS is a biotechnology company applying artificial intelligence and machine learning to drug discovery and diagnostics. Its proprietary platform analyses transcriptomic, genomic, and proteomic datasets to identify novel biological targets and disease drivers. The company offers fee-for-service target…
Digital cognitive assessment and CNS clinical trial software platform
Cambridge Cognition provides digital cognitive assessment and clinical trial technology for central nervous system drug development. Its validated computerised tests measure memory, attention and executive function across conditions including Alzheimer's disease and schizophrenia. The company also offers electronic…
Nanotechnology drug delivery platform for precision medicines
Nanomerics is a UK speciality pharmaceutical company developing precision medicines using its proprietary technology, a polymer nanotechnology platform that improves the bioavailability and targeting of water-insoluble drugs and peptides. The technology enables delivery via nasal, ocular, oral, and blood-brain barrier…
Small molecule inhibitors targeting somatic expansion in neurodegeneration
LoQus23 Therapeutics is a biotechnology company developing oral small molecule inhibitors of DNA mismatch repair for the treatment of Huntington's disease and other triplet repeat expansion disorders. The company targets MutSβ, a protein complex whose aberrant activity drives somatic expansion and progressive…
Targeted protein degradation platform for neurodegenerative disease
TRIMTECH Therapeutics is a biotechnology company developing small-molecule degraders that selectively remove disease-causing protein aggregates while preserving the functional, non-aggregated forms of the same proteins. The platform is built on research into the E3 ubiquitin ligase TRIM21, conducted over nearly two…
RBC derived nanoparticles for RNA delivery to brain and immune cells
Crane Biosciences is a biotechnology company developing a non-immunogenic RNA delivery platform based on nanoparticles derived from red blood cell membranes. By using the body's own cellular architecture as a delivery vehicle, the platform achieves substantially higher in vivo delivery efficiency to target tissues…
Tunable covalent chemistry platform for neurodegenerative disease
Dunad Therapeutics is a drug discovery biotech developing small molecule therapies for neurodegenerative diseases including ALS, frontotemporal dementia, and Parkinson's disease. Its platform combines tunable covalent chemistry with targeted protein degradation, using monovalent small molecules that form durable bonds…
Stem cell-derived exosome platform for targeted drug delivery
ReNeuron is a biotechnology company developing a stem cell-derived exosome platform for targeted therapeutic delivery. Founded on over two decades of stem cell science, including the world's first clinical trial of conditionally immortalised neural stem cell therapy for stroke disability, the company has pivoted to…
Autophagy-enhancing small molecule drugs for neurodegeneration and rare disease
Samsara Therapeutics is a drug discovery company developing first-in-class small molecule therapeutics that restore autophagy, the cellular process of degrading and recycling damaged proteins, which declines with age and is dysfunctional in multiple diseases. Its platform identifies and chemically optimises…
Next-generation targeted protein degradation therapeutics
Amphista Therapeutics is a Cambridge-based biopharmaceutical company developing next-generation targeted protein degradation medicines. Its proprietary platform generates bifunctional small molecule degraders that harness a broader range of the cell's protein-degrading machinery than existing approaches, enabling…
AI analysis of brain MRI for neurological diagnosis and prognosis
Ainostics is a medical artificial intelligence company developing software that analyses brain scans and clinical data to support the diagnosis and prognosis of neurological disorders. Its platform derives detailed measures of brain tissue structure from routine MRI and compares them with healthy populations to detect…
Preclinical DMPK, bioanalysis and toxicology CRO
Pharmidex is a UK contract research organisation providing preclinical drug discovery and development services across DMPK, bioanalysis, toxicology, histology and in vitro ADME. Operating under GLP and GCP accreditation from its Hatfield facility, the company supports programmes in oncology, CNS, respiratory and…
AI-driven combinatorial analytics platform for chronic disease biology
PrecisionLife is a computational biology company applying AI-driven combinatorial analytics to complex chronic diseases. Its platform identifies causal biological mechanisms and patient subgroups at a resolution not achievable by conventional genomic methods, enabling novel drug target discovery, patient…
Specialty biopharma covering oncology, neurology, and fertility
Merck Serono Limited is the UK commercial subsidiary of Merck KGaA's Healthcare division, a German science and technology company founded in 1668. The UK operation markets prescription medicines across oncology, neurology, immunology, endocrinology, and fertility. Key products include Erbitux for colorectal and…
Molecular disease research spanning genetics, neurobiology and intracellular infections
Cambridge Institute for Medical Research is a University of Cambridge institute studying the molecular mechanisms of human disease. Researchers investigate protein folding, cellular quality control, membrane trafficking and organelle function, focusing on rare genetic disorders, neurological conditions and…